By Sheeba M., Weedstock Market Intelligence | Friday, October 2, 2026 | 7:00 PM ET
Cannabis equities wrapped up the first full trading week of Q4 2026 with measured optimism as multi-state operators and licensed producers navigated pre-weekend positioning ahead of anticipated DEA regulatory pipeline developments. The MSOS ETF closed Friday’s session modestly in the green, posting its third consecutive positive weekly close. Market participants are now squarely focused on what the weekend regulatory news cycle may deliver before Monday’s open.
Friday Closing Tape: Key Names
Curaleaf Holdings (CURLF) closed near intraday highs after defending key technical support at its 50-day moving average. Institutional order flow data from the final 30 minutes of Friday’s session reflected measured accumulation — consistent with funds building positions ahead of what they believe will be a catalyst-rich October. Curaleaf’s 280E tax liability exposure remains one of the largest among MSOs, making it a high-beta play on rescheduling finalization.
Green Thumb Industries (GTBIF) outperformed the broader cannabis sector for the second consecutive session, buoyed by channel checks pointing to continued Illinois dispensary strength. Green Thumb’s premium retail brand positioning and conservative balance sheet management have made it a favored holding among cannabis-specialist fund managers heading into Q4 earnings season.
Trulieve Cannabis (TCNNF) closed roughly flat after digesting Thursday’s gains. Florida continues to be Trulieve’s core earnings engine, and weekend foot traffic data from the state’s medical and adult-use markets will inform how analysts revise Q3 same-store sales estimates heading into the earnings call.
Tilray Brands (TLRY) dipped modestly on light profit-taking following Thursday’s German market-driven run. Despite the pullback, Tilray’s dual narrative — domestic Canadian market share and European export growth — remains intact. Q1 FY2027 guidance, expected mid-October, will be the next major catalyst for the stock.
After-Hours Watch: DEA Rescheduling Pipeline
The DEA’s Office of Diversion Control published no new Federal Register actions after Friday’s market close, but industry sources indicate that internal DOJ final sign-off language for the cannabis rescheduling Final-2 rule is in its last review stages. A formal Federal Register filing — even over a weekend — would trigger gap-up conditions at Monday’s open across the entire cannabis sector.
Options market data tells a clear story: implied volatility on weekly cannabis contracts expiring October 9 has risen materially through the week. The market is pricing a non-trivial probability of a weekend catalyst event. Traders monitoring CURLF, GTBIF, and TCNNF should have alert systems active on federalregister.gov and DEA.gov through the weekend.
Monday October 5 Pre-Market Catalyst Preview
Three specific catalysts to monitor before Monday’s 9:30 AM ET open:
- DEA Federal Register weekend filing: The highest-probability catalyst for a Monday gap-up. Any rescheduling rule progress published between now and Sunday night would be the most significant cannabis regulatory event since the proposed rule publication. Monitor DEA.gov and federalregister.gov for cannabis-related Diversion Control filings.
- Organigram September sell-through data (OGI): Canadian provincial reporting for September 2026 retail sell-through is expected early next week. Organigram’s domestic market share trajectory and gross margin performance have been closely watched since its recent strategic pivot toward higher-margin premium SKUs.
- Canopy Growth German export pipeline (CGC): Canopy’s B2B device export business serving Germany’s rapidly growing medical cannabis market remains an underappreciated revenue stream. Any weekend announcement formalizing Q4 supply agreements would be incrementally bullish for CGC heading into Monday’s open.
Q4 2026 Setup: The Convergence Trade
Cannabis investors entering Q4 face a historically compelling setup: three major catalysts converging within a 90-day window. First, DEA rescheduling finalization removes the sector’s most significant regulatory overhang. Second, Q3 MSO earnings (beginning mid-October) will reveal whether operational leverage improvements have materialized despite the 280E drag. Third, any Congressional movement on SAFE Banking or standalone 280E relief before year-end could represent a genuine valuation re-rating event.
Investors who have been structurally underweight cannabis through Q3’s range-bound trading may view any October weakness as an accumulation opportunity before the catalyst window opens fully. Position sizing ahead of the DEA catalyst is a key portfolio management question heading into next week.
Risk factors to watch: Macro risk-off rotation ahead of October CPI data, any DOJ delay in Final-2 sign-off, and Canadian dollar weakness affecting USD-reported LP earnings revisions.
Monitor all cannabis tickers covered in this report via the Weedstock Tracker. Market intelligence provided for informational purposes only and does not constitute investment advice.